Frequent genetic aberrations in the CDK4 pathway in acral melanoma indicate the potential for CDK4/6 inhibitors in targeted therapy
Y Kong, X Sheng, X Wu, J Yan, M Ma, J Yu, L Si… - Clinical Cancer …, 2017 - AACR
Purpose: Effective therapies for the majority of metastatic acral melanoma patients have not
been established. Thus, we investigated genetic aberrations of CDK4 pathway in acral …
been established. Thus, we investigated genetic aberrations of CDK4 pathway in acral …
Genetic aberrations in the CDK4 pathway are associated with innate resistance to PD-1 blockade in Chinese patients with non-cutaneous melanoma
J Yu, J Yan, Q Guo, Z Chi, B Tang, B Zheng, J Yu… - Clinical Cancer …, 2019 - AACR
Purpose: PD-1 checkpoint blockade immunotherapy induces long and durable response in
patients with advanced melanoma. However, only a subset of patients with melanoma …
patients with advanced melanoma. However, only a subset of patients with melanoma …
[HTML][HTML] Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients
J Yu, X Wu, J Yan, H Yu, L Xu, Z Chi, X Sheng… - Journal of Hematology & …, 2018 - Springer
Background Chimeric antigen receptor (CAR)-engineered T cells have demonstrated promising
clinical efficacy in patients with B cell lymphoma. However, the application of CAR-T cell …
clinical efficacy in patients with B cell lymphoma. However, the application of CAR-T cell …
[HTML][HTML] miR-let-7b and miR-let-7c suppress tumourigenesis of human mucosal melanoma and enhance the sensitivity to chemotherapy
…, L Si, X Sheng, Z Chi, L Xu, S Yu, T Xu, J Yan… - Journal of Experimental …, 2019 - Springer
Background Mucosal melanoma with poor prognosis is a common histopathologic subtype
of melanoma among Chinese and other Asian peoples. Regulated microRNAs (miRNAs) …
of melanoma among Chinese and other Asian peoples. Regulated microRNAs (miRNAs) …
[HTML][HTML] Prognostic role of tumor mutation burden combined with immune infiltrates in skin cutaneous melanoma based on multi-omics analysis
J Yan, X Wu, J Yu, Y Zhu, S Cang - Frontiers in Oncology, 2020 - frontiersin.org
Tumor mutation burden (TMB) and tumor infiltrating lymphocytes have been well-recognized
as molecular determinants of immunotherapeutic responsiveness in many types of cancer. …
as molecular determinants of immunotherapeutic responsiveness in many types of cancer. …
[HTML][HTML] Systemic immune-inflammation index and circulating T-cell immune index predict outcomes in high-risk acral melanoma patients treated with high-dose …
…, X Sheng, C Cui, J Dai, M Ma, H Tang, T Xu, J Yan… - Translational …, 2017 - Elsevier
High-dose interferon alfa-2b (IFN-α-2b) improves the survival of patients with high-risk
melanoma. We aimed to identify baseline peripheral blood biomarkers to predict the outcome of …
melanoma. We aimed to identify baseline peripheral blood biomarkers to predict the outcome of …
[HTML][HTML] Impact of HER2 on prognosis and benefit from adjuvant chemotherapy in stage II/III gastric cancer patients: a multicenter observational study
…, L Zhao, N Zhang, W Han, K Liu, J Yan… - … Journal of Surgery, 2023 - journals.lww.com
Background: Human epidermal growth factor receptor 2 (HER2) is a well-developed therapeutic
target in breast and gastric cancer (GC). However, the impact of HER2 on survival and …
target in breast and gastric cancer (GC). However, the impact of HER2 on survival and …
[HTML][HTML] Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy
H Yu, M Ma, J Yan, L Xu, J Yu, J Dai, T Xu… - Journal of translational …, 2017 - Springer
Background Coexistence of enhancer of zeste homolog 2 (EZH2) and BRAF gene aberrations
has been described in many cancer types. In this study, we aim to explore the coexistence …
has been described in many cancer types. In this study, we aim to explore the coexistence …
[HTML][HTML] Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma
X Wu, J Yan, J Dai, M Ma, H Tang, J Yu… - Oncology …, 2017 - spandidos-publications.com
B-Raf proto-oncogene serine/threonine kinase (BRAF) V600E is the most common kinase‑activating
mutation and is associated with poor prognosis in melanoma. However, the clinical …
mutation and is associated with poor prognosis in melanoma. However, the clinical …
[HTML][HTML] Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor
… Jun Guo and Yan Kong were involved in conception and design of the study. Dr. Junya Yan
performed and evaluated the experiment. Drs. Xiaowen Wu, Jiayi Yu, Huan Yu, Tianxiao Xu, …
performed and evaluated the experiment. Drs. Xiaowen Wu, Jiayi Yu, Huan Yu, Tianxiao Xu, …